| 2022-DAVI-69921 | |
| Researchers at Purdue University have developed fast-acting antidotes to reverse cyanide poisoning. Some previous antidotes have involved the use of Pt(II) or Pt(IV) salts formulated with DMSO followed by dilution in phosphate-buffered saline. However, these antidotes are ineffective when administered intramuscularly. The Purdue researchers propose complexes of Pt(II) coordinated with amine and bidentate sulfur ligands. These complexes had enhanced reactivity toward cyanide in vitro and fully recapitulated in vivo cyanide rescue in zebrafish and mouse models. The cyanide addition products yielded tetracyanoplatinate(II), translating to a stoichiometry of 1:4 Pt to each cyanide scavenger. These new agents demonstrate a robust and enhanced potency over the DMSO-containing complexes using intramuscular administration in mouse and rabbit models of cyanide toxicity. Using the zebrafish model with these Pt(II) complexes, no acute cardiotoxicity was detected, and dose levels required to reach lethality were greater than one hundred times the effective dose. Technology Validation: One of the researchers' compounds recapitulated in vivo cyanide rescue in 5/5 mice and maintained its efficacy 7 days after formulation. Related Publication: Identification of Platinum(II) Sulfide Complexes Suitable as Intramuscular Cyanide Countermeasures. Chemical Research in Toxicology 2022 35 (11), 1983-1996. DOI: 10.1021/acs.chemrestox.2c00157 Advantages: - The antidotes are suitable for intramuscular injection - Complexes coordinate in a 1:4 Pt-to-cyanide ratio, providing higher scavenging action than state-of-the-art - Many of the antidote complexes are highly water-soluble - The antidote complexes demonstrated no cardiotoxicity in vivo testing on zebrafish Applications: - Antidotes for cyanide poisoning |
|
|
Jul 29, 2022
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
